36 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported … knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived … expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases … and Health Sciences in Washington, DC. “Moderate-severe AD is a chronic disease with high patient-burden. Multiple unmet needs remain with current
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
rademikibart global Phase 2 program for patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in 2022 due to enrollment difficulties, and (iii) higher
6-K
EX-99.1
juf hguftq
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.1
qrdiqy3o6 ho3x
5 Jun 23
Current report (foreign)
4:28pm
6-K
EX-99.1
16ubrqu7g bu
1 Jun 23
Current report (foreign)
4:24pm
6-K
EX-99.1
jdwj94k ot
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
6-K
9yd m0ficlkj5
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
mpusy0s5wnp vzas
30 Aug 22
Current report (foreign)
4:01pm
F-3/A
j686rxgedq
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
F-3/A
gdhpq
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
EX-99.1
w69876itple9uc0
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
o6aus92unl 7ufl4o59
15 Apr 22
Shelf registration (foreign)
5:27pm
6-K
EX-99.1
um28n8 79b
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
20-F
m5dmoc8 jc4hfk39tu
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
gzurio5hm3yh1u6ww
16 Feb 22
Current report (foreign)
4:01pm
6-K
EX-99.1
f7w8qy669 p79tqj
5 Jan 22
Current report (foreign)
5:24pm